CA
NZ
UK
AU
IND
US
…
BlinkLab Limited focuses on the development and commercialization of intellectual property related to smartphone-based neurobehavioural testing. Its smartphone-based application serves as a device for conducting neurobehavioral evaluations and objective sensorimotor biomarkers, which provides scientific support for future regulatory approval and clinical adoption. The company's application also enables remote and rapid testing to aid research on neurodevelopmental and neurodegenerative conditions such as schizophrenia, autism, attention deficit hyperactivity disorder (ADHD), and various forms of dementia. The company was incorporated in 2021 and is based in Perth, Australia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public information on Blinklab Ltd (ASX:BB1) is limited and the company provides minimal detail on its core operations, leaving its precise business activities unclear. Long-term growth drivers are not disclosed, so potential upside would depend on future product or commercial execution that requires confirmation; the stock may appeal only to investors comfortable with high-information uncertainty.
Material risks include sparse disclosure and transparency, low share liquidity, dependence on additional financing, an unproven business model with execution risk, and potential regulatory or market acceptance challenges.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Income before tax | -7.22M | -5.71M | -1.75M | -0.68M | -0.49M |
| Net income | -7.22M | -5.71M | -1.75M | -0.68M | -0.49M |
| Selling general administrative | 2.72M | 3.28M | 1.51M | 0.61M | 0.46M |
| Reconciled depreciation | 0.39M | - | 0.08M | 0.06M | - |
| Operating income | -8.42M | -5.70M | -1.75M | -0.68M | -0.48M |
| Interest expense | 0.02M | - | 0.00M | 0.00M | - |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | 0.39M | -0.01M | 0.00M | 0.00M | 0.00M |
| Net interest income | 0.37M | - | -0.00M | -0.00M | - |
| Total revenue | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | - | 5.70M | - | - | - |
| Total other income expense net | 0.84M | - | 0.04M | - | - |
| Net income from continuing ops | -7.22M | - | -1.75M | -0.68M | - |
| Net income applicable to common shares | - | -5.71M | -1.75M | -0.68M | -0.49M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Total assets | 20.56M | 9.67M | 6.87M | 0.37M | 0.91M |
| Intangible assets | 1.34M | 0.42M | 0.35M | 0.26M | 0.21M |
| Other current assets | - | 0.19M | - | - | - |
| Total liab | 1.06M | 0.70M | 0.39M | 0.33M | 0.19M |
| Total stockholder equity | 19.50M | 8.97M | 6.48M | 0.04M | 0.72M |
| Common stock | - | 14.89M | - | - | 1.20M |
| Capital stock | 30.13M | - | 9.11M | 1.20M | - |
| Retained earnings | -15.84M | -5.92M | -2.91M | -1.16M | -0.49M |
| Cash | 7.88M | 1.71M | 3.02M | 0.05M | 0.62M |
| Cash and equivalents | - | 7.00M | - | - | - |
| Total current liabilities | 0.74M | 0.64M | 0.27M | 0.32M | 0.18M |
| Short term debt | - | 0.00M | - | - | 0.00M |
| Property plant equipment | - | 0.15M | - | - | 0.08M |
| Total current assets | 18.73M | 9.10M | 6.31M | 0.05M | 0.62M |
| Short term investments | 10.07M | 0.00M | 3.00M | - | - |
| Net receivables | - | - | - | 0.00M | 0.01M |
| Accounts payable | 0.47M | - | 0.13M | 0.31M | - |
| Non current assets total | 1.83M | - | 0.56M | 0.32M | - |
| Capital lease obligations | 0.39M | - | 0.17M | 0.02M | - |
| Long term debt total | - | 0.06M | - | - | 0.02M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Investments | -10.07M | - | -3.14M | -0.08M | - |
| Total cashflows from investing activities | - | 2.86M | -3.14M | -0.08M | -0.26M |
| Total cash from financing activities | 16.77M | 6.99M | 7.87M | -0.01M | 1.19M |
| Net income | -7.22M | - | -1.75M | -0.68M | - |
| Change in cash | -0.84M | 5.69M | 2.97M | -0.57M | 0.62M |
| Begin period cash flow | 8.71M | - | 0.05M | 0.62M | - |
| End period cash flow | 7.88M | - | 3.02M | 0.05M | - |
| Total cash from operating activities | - | -4.17M | -1.75M | -0.47M | -0.30M |
| Issuance of capital stock | 18.09M | - | 8.41M | - | - |
| Other cashflows from investing activities | - | 3.00M | -3.00M | - | - |
| Sale purchase of stock | -1.25M | 7.55M | 8.41M | 0.00M | 1.20M |
| Other cashflows from financing activities | - | -0.53M | -0.50M | - | - |
| Capital expenditures | 1.30M | 0.14M | 0.14M | 0.08M | 0.26M |
| Change in working capital | - | 0.37M | 0.03M | -0.00M | -0.00M |
| Free cash flow | -7.54M | - | -1.90M | -0.56M | - |
Sector: Healthcare Industry: Health Information Services
|
Stock Name
|
Change
(AUD) |
Price
(AUD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
|---|---|---|---|---|---|---|
| BB1 Blinklab Ltd |
0.01 0.89% |
0.57 | - | - | 85.42 | 5.20 |
| PME Pro Medicus Ltd |
-3.10 1.49% |
205.13 | 81.98 | 106.38 | 83.13 | 43.70 |
| 4DX 4DMEDICAL Ltd |
-0.13 5.39% |
2.28 | - | - | 205.57 | 8.53 |
| CGS Cogstate Ltd |
-0.09 2.66% |
3.29 | 33.80 | 27.86 | 9.59 | 6.95 |
| AYA ARTRYA Ltd |
- -% |
3.50 | - | - | 20505.14 | 7.00 |
BlinkLab Limited focuses on the development and commercialization of intellectual property related to smartphone-based neurobehavioural testing. Its smartphone-based application serves as a device for conducting neurobehavioral evaluations and objective sensorimotor biomarkers, which provides scientific support for future regulatory approval and clinical adoption. The company's application also enables remote and rapid testing to aid research on neurodevelopmental and neurodegenerative conditions such as schizophrenia, autism, attention deficit hyperactivity disorder (ADHD), and various forms of dementia. The company was incorporated in 2021 and is based in Perth, Australia.
| Name | Title | Year Born |
|---|---|---|
| Dr. Hendrikus Johannes Boele M.D., Ph.D. | Founder & CEO | NA |
| Mr. Cornelis Pieter Boele | Founder & Chief Technology Officer | NA |
| Dr. Sebastiaan K.E Koekkoek | Founder & Chief Scientific Officer | NA |
| Dr. Anton Uvarov BioChem, MBA, MedGen, Ph.D. | Executive Director | NA |
| Ms. Kamille Dietrich | Company Secretary | NA |
| Mr. Christopher Achurch | Company Secretary | NA |
| Dr. Hendrikus Johannes Boele M.D., Ph.D. | Founder & CEO | NA |
| Mr. Cornelis Pieter Boele | Founder & Chief Technology Officer | NA |
| Dr. Sebastiaan K.E Koekkoek | Founder & Chief Scientific Officer | NA |
| Dr. Anton Uvarov BioChem, MBA, MedGen, Ph.D. | Executive Director | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.61%
Communication Services
-0.21%
Consumer Cyclical
-0.26%
Consumer Defensive
-0.37%
Energy
+0.23%
Financial Services
-0.43%
Financials
+0.39%
Healthcare
+0.88%
Industrials
+0.36%
Real Estate
-0.51%
Technology
+1.35%
Utilities
+0.19%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...